From the SolidarMed, Partnerships for Health, Maseru, Lesotho.
Institute of Global Health, University of Geneva, Geneva, Switzerland.
Pediatr Infect Dis J. 2022 Mar 1;41(3):e75-e80. doi: 10.1097/INF.0000000000003415.
Children living with HIV and taking antiretroviral therapy (ART) are a priority group for routine viral load (VL) monitoring. As per Lesotho guidelines, a VL ≥1000 copies/mL ("unsuppressed") should trigger adherence counseling and a follow-up VL; 2 consecutive unsuppressed VLs ("virologic failure") qualify for switching to second-line ART, with some exceptions. Here, we describe the pediatric VL cascade in Lesotho.
In a prospective open cohort study comprising routine VL results from 22 clinics in Lesotho, we assessed outcomes along the VL cascade for children who had at least 1 VL test from January 2016 through June 2020. Data were censored on February 10, 2021.
In total, 1215 children received 5443 VL tests. The median age was 10 years (interquartile range 7-13) and 627/1215 (52%) were female; 362/1215 (30%) had at least 1 unsuppressed VL. A follow-up VL was available for 325/362 (90%), although only for 159/362 (44%) within 6 months of the first unsuppressed VL. Of those with a follow-up VL, 172/329 (53%) had virologic failure and 123/329 (37%) qualified for switching to second-line ART. Of these, 55/123 (45%) were ever switched, although only 9/123 (7%) were switched within 12 weeks of the follow-up VL. Delays were more pronounced in rural facilities. Overall, 100/362 (28%) children with an unsuppressed VL received a timely follow-up VL and, if required, a timely regimen switch.
Despite access to VL monitoring, clinical management was suboptimal. HIV programs should prioritize timely clinical action to maximize the benefits of VL monitoring.
儿童艾滋病毒感染者和接受抗逆转录病毒治疗(ART)的儿童是常规病毒载量(VL)监测的重点人群。根据莱索托的指导方针,VL≥1000 拷贝/毫升(“未抑制”)应触发依从性咨询和随访 VL;两次连续未抑制 VL(“病毒学失败”)有资格改用二线 ART,但有一些例外。在这里,我们描述了莱索托的儿科 VL 级联。
在一项包括莱索托 22 个诊所常规 VL 结果的前瞻性开放队列研究中,我们评估了 2016 年 1 月至 2020 年 6 月期间至少有 1 次 VL 检测的儿童沿着 VL 级联的结果。数据于 2021 年 2 月 10 日截止。
共有 1215 名儿童接受了 5443 次 VL 检测。中位年龄为 10 岁(四分位距 7-13),627/1215(52%)为女性;362/1215(30%)有至少 1 次未抑制 VL。尽管只有 159/362(44%)在第一次未抑制 VL 后 6 个月内获得了随访 VL,但 325/362(90%)的儿童获得了随访 VL。在有随访 VL 的儿童中,172/329(53%)发生病毒学失败,123/329(37%)有资格改用二线 ART。其中,55/123(45%)已转换,尽管只有 9/123(7%)在随访 VL 后 12 周内转换。在农村地区,延迟更为明显。总的来说,362 名有未抑制 VL 的儿童中有 100/362(28%)接受了及时的随访 VL,如果需要,也接受了及时的方案转换。
尽管可以进行 VL 监测,但临床管理仍不理想。艾滋病毒规划应优先及时采取临床行动,以最大限度地发挥 VL 监测的效益。